NCT06318845View on ClinicalTrials.gov

Phase 1 Study of DHP2302R1 and DHP2302R2 in Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

March 4, 2024

Primary Completion Date

April 26, 2024

Study Completion Date

May 7, 2024

Conditions
Healthy Volunteers
Interventions
DRUG

DHP2302R1

75 mg per dose, once daily

DRUG

DHP2302R2

50 mg per dose, once daily

Trial Locations (1)

08779

H Plus Yangji Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Daehwa Pharmaceutical Co., Ltd.

INDUSTRY

NCT06318845 - Phase 1 Study of DHP2302R1 and DHP2302R2 in Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter